342 related articles for article (PubMed ID: 21790283)
21. Targeting interleukin (IL) 5 for asthma and hypereosinophilic diseases.
Stein ML; Munitz A
Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):201-9. PubMed ID: 20807192
[TBL] [Abstract][Full Text] [Related]
22. L6. Eosinophilic granulomatosis with polyangiitis: future therapies.
Moosig F
Presse Med; 2013 Apr; 42(4 Pt 2):510-2. PubMed ID: 23453508
[No Abstract] [Full Text] [Related]
23. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
24. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
25. L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
Cordier JF; Cottin V; Guillevin L; Bel E; Bottero P; Dalhoff K; Humbert M; Lazor R; Sinico RA; Sivasothy P; Wechsler ME
Presse Med; 2013 Apr; 42(4 Pt 2):507-10. PubMed ID: 23490637
[No Abstract] [Full Text] [Related]
26. Diagnoses associated with peripheral blood eosinophilia: A 5-year review.
Leverone N; Tran S; Barry J; Akuthota P
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):597-598. PubMed ID: 34391899
[No Abstract] [Full Text] [Related]
27. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
28. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
29. Mepolizumab-based therapy in asthma: an update.
Walsh GM
Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
[TBL] [Abstract][Full Text] [Related]
30. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
Kuruvilla M
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
[No Abstract] [Full Text] [Related]
31. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
32. Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease.
Berti A; Boukhlal S; Groh M; Cornec D
Expert Rev Clin Immunol; 2020 Jan; 16(1):51-61. PubMed ID: 31762336
[No Abstract] [Full Text] [Related]
33. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
34. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis.
Condreay LD; Parham LR; Qu XA; Steinfeld J; Wechsler ME; Raby BA; Yancey SW; Ghosh S
Rheumatol Int; 2020 Aug; 40(8):1301-1307. PubMed ID: 32009195
[TBL] [Abstract][Full Text] [Related]
37. Technology evaluation: mepolizumab, GlaxoSmithKline.
Gnanakumaran G; Babu KS
Curr Opin Mol Ther; 2003 Jun; 5(3):321-5. PubMed ID: 12870444
[TBL] [Abstract][Full Text] [Related]
38. Eosinophils and interleukin-5: the debate continues.
Kay AB; Menzies-Gow A
Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
[No Abstract] [Full Text] [Related]
39. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions.
Walsh GM
Curr Opin Mol Ther; 2009 Jun; 11(3):329-36. PubMed ID: 19479666
[TBL] [Abstract][Full Text] [Related]
40. Hypereosinophilic syndrome presenting acutely with neurologic signs.
Brunet BA; Sugg RM; Stewart P
Ann Allergy Asthma Immunol; 2018 May; 120(5):461-464. PubMed ID: 29501486
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
